Novo Nordisk lowers full-year profit guidance in new CEO's maiden quarter

Pedersen and Maggie Fick COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk lowered its full-year profit and sales forecast on ...

Novo Nordisk loses further ground in obesity market

Novo Nordisk is continuing to lose ground in the obesity and diabetes markets, with the Danish drugmaker saying it expected ...
pharmaphorum

Novo Nordisk cuts guidance again on weaker GLP-1 growth

The financial results show top-line sales growth in the first nine months of the year of 12% to DKK 230 billion ($35.4 ...

Novo Nordisk accepts Ozempic, Wegovy and Rybelsus prices in US Medicare negotiations

Novo Nordisk said on Wednesday it has accepted the U.S. Inflation Reduction Act (IRA)'s maximum fair price for its diabetes ...

Novo Nordisk’s weight-loss drug Wegovy could soon have a new sales outlet in the U.S.

Telehealth company Hims & Hers Health Inc. said late Monday it is in “active discussions” with Denmark’s Novo Nordisk A/S to ...

Novo Nordisk cuts profit forecast as new CEO faces rocky start

Novo Nordisk lowers its 2025 profit forecast as new CEO Mike Doustdar faces rising competition, leadership changes, and a ...

Ozempic maker Novo Nordisk lowers growth outlook for its weight loss drugs as pricing pressures mount

Novo launched a rival bid to acquire American obesity biotech firm Metsera last week, superseding an offer for the firm from ...

Novo Nordisk's sales increased by 12% in Danish kroner and by 15% at CER in the first nine months of 2025; R&D pipeline progress continues

Bagsværd, 5 November, 2025 - Financial report for the period 1 January 2025 to 30 September 2025 Operating profit increased ...